These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 17485924

  • 1. Effects of pimobendan for mitral valve regurgitation in dogs.
    Kanno N, Kuse H, Kawasaki M, Hara A, Kano R, Sasaki Y.
    J Vet Med Sci; 2007 Apr; 69(4):373-7. PubMed ID: 17485924
    [Abstract] [Full Text] [Related]

  • 2. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Apr; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 3. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease.
    Ouellet M, Bélanger MC, Difruscia R, Beauchamp G.
    J Vet Intern Med; 2009 Apr; 23(2):258-63. PubMed ID: 19143935
    [Abstract] [Full Text] [Related]

  • 4. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Apr; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

  • 5. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P.
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE.
    J Vet Intern Med; 2009 Nov; 23(6):1190-6. PubMed ID: 19780931
    [Abstract] [Full Text] [Related]

  • 7. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs.
    Häggström J, Hansson K, Kvart C, Karlberg BE, Vuolteenaho O, Olsson K.
    Am J Vet Res; 1997 Jan; 58(1):77-82. PubMed ID: 8989501
    [Abstract] [Full Text] [Related]

  • 8. The effect of pimobendan on left atrial pressure in dogs with mitral valve regurgitation.
    Suzuki S, Fukushima R, Ishikawa T, Hamabe L, Aytemiz D, Huai-Che H, Nakao S, Machida N, Tanaka R.
    J Vet Intern Med; 2011 Jan; 25(6):1328-33. PubMed ID: 22092624
    [Abstract] [Full Text] [Related]

  • 9. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Jan; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 10. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM, Menciotti G, Braz-Ruivo L, Crosara S, Häggström J, Borgarelli M.
    Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
    [Abstract] [Full Text] [Related]

  • 11. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease".
    Corcoran B, Culshaw G, Dukes-McEwan J, French A, Smith S, Swift S.
    J Vet Intern Med; 2008 Sep; 22(2):243; author reply 245. PubMed ID: 18371020
    [No Abstract] [Full Text] [Related]

  • 12. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F, Neves J, Maddox TW, Hodgkiss-Geere HM, Bode EF, Dukes-McEwan J.
    Open Vet J; 2020 Jan; 9(4):375-383. PubMed ID: 32042661
    [Abstract] [Full Text] [Related]

  • 13. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study.
    Chetboul V, Lefebvre HP, Sampedrano CC, Gouni V, Saponaro V, Serres F, Concordet D, Nicolle AP, Pouchelon JL.
    J Vet Intern Med; 2007 Jan; 21(4):742-53. PubMed ID: 17708394
    [Abstract] [Full Text] [Related]

  • 14. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded and randomized study".
    Le Bobinnec G.
    J Vet Intern Med; 2008 Jan; 22(2):243-4; author reply 245-6. PubMed ID: 18371019
    [No Abstract] [Full Text] [Related]

  • 15. Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy.
    Tissier R, Chetboul V, Moraillon R, Nicolle A, Carlos C, Enriquez B, Pouchelon JL.
    Cardiovasc Toxicol; 2005 Jan; 5(1):43-51. PubMed ID: 15738584
    [Abstract] [Full Text] [Related]

  • 16. Effects of 4 classes of cardiovascular drugs on ventricular function in dogs with mitral regurgitation.
    Nakayama T, Nishijima Y, Miyamoto M, Hamlin RL.
    J Vet Intern Med; 2007 Jan; 21(3):445-50. PubMed ID: 17552449
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N, Nolte I, Wall L, Sehn M, Raue J, Pilgram A, Rumstedt K, Bach JP.
    BMC Vet Res; 2019 Jul 09; 15(1):237. PubMed ID: 31288807
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ, French AT, Van Israël N, Smith SG, Swift ST, Lee AJ, Corcoran BM, Dukes-McEwan J.
    J Small Anim Pract; 2005 Mar 09; 46(3):121-30. PubMed ID: 15789807
    [Abstract] [Full Text] [Related]

  • 20. Hemodynamic profile of the cardiotonic agent pimobendan.
    van Meel JC, Diederen W.
    J Cardiovasc Pharmacol; 1989 Mar 09; 14 Suppl 2():S1-6. PubMed ID: 2478784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.